Day: March 24, 2025

Advancing a broad, potential best-in-class orexin receptor 2 (OX2R) agonist franchise with key data readouts expected in 2025ORX750 Phase 2a CRYSTAL-1 study for the treatment of narcolepsy type 1 (NT1), narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH) well underway and on track with data expected across all three indications in 2025 with first-in-class potential in NT2 and IH ORX142 in IND-enabling studies for the treatment of neurological and neurodegenerative disorders; Clinical data in acutely sleep-deprived healthy volunteers planned for 2025 ORX489 in IND-enabling studies for the treatment of neuropsychiatric disordersBOSTON and LONDON, March 24, 2025 (GLOBE NEWSWIRE) — Centessa Pharmaceuticals plc (Nasdaq: CNTA), a clinical-stage pharmaceutical company, today reported recent business highlights and financial...

FDA stated in written correspondence for a START pilot program meeting that it is open to considering skin FXN concentration as a reasonably likely surrogate endpoint in support of an accelerated approval FDA recommended measuring skin FXN concentrations to support evidence of effectiveness for accelerated approval pathway and acknowledged submitted data appear sufficient to support relationship between increased skin FXN concentrations and relevant tissues such as heart, dorsal root ganglia and skeletal muscle Larimar is continuing discussions with FDA on the adequacy of the safety data set to support BLA submission BLA seeking accelerated approval targeted for submission by year-end 2025 FDA and EMA feedback obtained on global Phase 3 study protocol; study planned to initiate in mid-2025 Topline 50 mg dose data from the OLE study and...

SAN FRANCISCO, March 24, 2025 (GLOBE NEWSWIRE) — Wag! Group Co. (the “Company” or “Wag!”; Nasdaq: PET), which strives to be the number one platform to solve the service, product, and wellness needs of the modern U.S. pet household, today announced financial results for the fourth quarter and full year ended December 31, 2024. The Company also announced that its Board of Directors (the “Board”) is advancing its review of strategic alternatives to identify opportunities to maximize value for shareholders, including potential investments, strategic partnerships, sale, merger, or other strategic transactions involving the Company or its assets. “Our Board and management team continues to believe in the strength of our business, the effectiveness of our strategic plan, and our ability to execute on our strategy to drive value for shareholders,”...

VANCOUVER, British Columbia, March 24, 2025 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG”, or the “Company”) announces the Company’s consolidated financial results for the year ended December 31, 2024. For details of the audited consolidated financial statements of the Company for the year ended December 31, 2024 (“2024 Financial Statements”) and management’s discussion and analysis for the year ended December 31, 2024 (“2024 MD&A”), please see the Company’s filings on the System for Electronic Document Analysis and Retrieval Plus (“SEDAR+”) at (www.sedarplus.ca) or on the Electronic Data Gathering, Analysis, and Retrieval (“EDGAR”) at (www.sec.gov).   All amounts herein are reported in thousands of United States dollars (“US$”) unless otherwise specified (C$ refers to thousands of Canadian dollars). KEY...

Additional alignment with FDA on LX2006 planned pivotal study including protein expression co-primary endpoint: based on improvements in LVMI across participants with abnormal LVMI at baseline, frataxin expression to be evaluated for any increase from baseline rather than numerical threshold Interim update from cohort 1 of LX2020 HEROIC-PKP2 Phase 1/2 trial: observed 71% and 115% increases in PKP2 protein expression in first two post-treatment biopsies; first participant evaluated 6-months after dosing experienced 67% reduction in premature ventricular contractions (PVCs) Completed enrollment of cohort 2 of LX2020 HEROIC-PKP2 Phase 1/2 trial; interim clinical data update expected in second half of 2025 LX2020 has been generally well tolerated with no treatment-related serious adverse events to date Cash, cash equivalents and investments...